TMC names latest cohort of health tech innovators for 2024 program

ready to grow

Here are the eight companies currently being accelerated by Texas Medical Center Innovation. Photo courtesy of TMC

The Texas Medical Center Innovation has named its new cohort of health tech companies it's currently accelerating.

This first batch of companies for 2024 was selected from last fall's TMC Bootcamp. Eight of the 10 startups from the bootcamp have moved on to the Accelerator for HealthTech.

"Hailing from diverse corners of the globe—from the tech corridors of Texas and California to Ireland and Australia—these companies converge with a shared mission—to move healthcare forward," Devin Dunn, head of the Accelerator for Health Tech, writes in a TMC blog post. "Through personalized mentorship and guidance, these eight companies are able to navigate complex challenges and refine their strategies, while leveraging the expertise of Texas Medical Center ecosystem to validate their innovations and drive real-world impact."

The selected companies include:

AcorAI, from Stockholm, Sweden, which is developing a first-of-its-kind, hand-held, scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for more than 64 million patients worldwide.
AirSeal, based in St. Louis, Missouri, which has developed a novel serum-based biomarker technology – circulating fatty acid synthase (cFAS) – that can diagnose cardiovascular and peripheral artery disease with high accuracy in both women and men.
Foxo, headquartered in Brisbane, Australia, serves as an interoperable tool designed to enhance clinical collaboration across the healthcare ecosystem. It enables secure, two-way communication with features such as video, voice, screen share, file sharing, and real-time messaging.
San Francisco-based Knowtex, an artificial intelligence-powered software writes medical documentation for you and assigns correct codes to ensure proper reimbursement.
NeuroBell, from Cork, Ireland, which is working on a novel medical device providing portable EEG monitoring with real-time and automated neonatal seizure alerts at the bedside.
Perth, Australia-based OncoRes Medical that's developing an intraoperative imaging technology to provide surgeons with real-time assessment of tissue microstructure.
From right here in Houston, Steradian Technologies, which has created RUMI, the first noninvasive, fully portable infectious disease diagnostic that costs the price of a latte. It uses novel photon-based detection to collect and diagnose infectious diseases in breath within 30 seconds.
TYBR, also based in Houston, created a flowable extracellular matrix hydrogel, crafted to safeguard healing tendons and ligaments from scarring and adhesions. The company originated from the TMCi’s Biodesign fellowship and now has entered into the Accelerator for HealthTech to sharpen its regulatory strategy, particularly in anticipation of FDA conversations.

Applications for the next Accelerator for HealthTech will open in May of this year.

Meet the latest global health tech startups to get an invite to Houston from TMC Innovation. Photo via tmc.edu

TMC names latest cohort of health tech startups for upcoming bootcamp

headed to Houston

The Texas Medical Center's innovation arm has again invited a set of health tech startups to mix and mingle with potential partners, investors, and customers in hopes to score a place in the HealthTech Accelerator.

For the 17th time, the TMC Innovation Factory is hosting its HealthTech Accelerator — starting first with announcing its bootcamp cohort, a process that includes bringing all 10 companies to Houston for valuable networking. A selection of the bootcamp will be invited into the full accelerator that will run into next spring.

The 10 selected companies with solutions from heart failure to chronic respiratory disease and more, according to TMC, include:

Acorai, from Stockholm, Sweden, which is developing a first-of-its-kind, hand-held, scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for more than 64 million patients worldwide.
Singapore-based Aevice Health, a connected care platform powered by the world’s smallest smart wearable stethoscope to support chronic respiratory disease patients through their continuum of care.
AirSeal, based in St. Louis, Missouri, which has developed a novel serum-based biomarker technology – circulating fatty acid synthase (cFAS) – that can diagnose cardiovascular and peripheral artery disease with high accuracy in both women and men.
Candlelit Care, a Charlotte, North Carolina-based point-of-care digital platform focused on the prevention of perinatal mental and anxiety disorders (PMADs) among Black women and birthing parents.
San Francisco-based Knowtex, an artificial intelligence-powered software writes medical documentation for you and assigns correct codes to ensure proper reimbursement.
NeuroBell, from Cork, Ireland, which is working on a novel medical device providing portable EEG monitoring with real-time and automated neonatal seizure alerts at the bedside.
Perth, Australia-based OncoRes Medical that's developing an intraoperative imaging technology to provide surgeons with real-time assessment of tissue microstructure.
From right here in Houston, Steradian Technologies, which has created RUMI, the first noninvasive, fully portable infectious disease diagnostic that costs the price of a latte. It uses novel photon-based detection to collect and diagnose infectious diseases in breath within 30 seconds.
Foxo, headquartered in Brisbane, Australia, serves as an interoperable tool designed to enhance clinical collaboration across the healthcare ecosystem. It enables secure, two-way communication with features such as video, voice, screen share, file sharing, and real-time messaging.
Thrive Health’s, from Vancouver, Canada, is a platform is a low-code framework for designing and delivering patient engagement solutions. Create tools that enable partners to close healthcare gaps quickly, strengthen care relationships, and improve patient experience and outcomes.

TMC Innovation's last bootcamp cohort was announced in May. The organization also recently named 16 digital health and medical device startups from the United Kingdom to a new accelerator formed in partnership with Innovate UK.

Earlier this fall, TMC formed a strategic partnership, or BioBridge, with the Netherlands.

Seventeen of the RBPC student teams walked away with investment prizes this year. Photo courtesy of Rice

Houston student startup competition doles out record-breaking more than $3M in prizes

show me the money

Over the weekend, Houston hosted what is known as the world’s largest and richest intercollegiate student startup competition, and a Texas team took the overall win and over $3 million in investment prizes were given out at the annual banquet.

The 2023 Rice Business Plan Competition was held May 11-13 and included mentoring, pitching, and networking for the 42 student teams with over 350 judges before culminating in over 80 prizes being announced. The $3.4 million in investment and in-kind prizes marks the largest yet for the 23-year-old competition.

"Judges told us that the quality of the startups at this year’s competition was the best ever,” says Catherine Santamaria, director of the RBPC, in the news release. “One judge went so far as to say that every startup this year was worthy of investment.”

Over 450 startups applied to the competition, and the 42 startups selected hailed from 35 universities from five countries. There were five categories: energy, clean tech and sustainability; life sciences and health care solutions; consumer products and services; hard tech; and digital enterprise. Based on the judges scores, seven startups reached the finals, and this year, three Texas teams made the finals, with two being from Rice University.

All 42 companies were eligible for investment or in-kind prizes, and, even though $1.75 million in prizes was expected to be awarded, some of this year's investors doubled — or even tripled — down on investment awards. While the finalists walked away with various in-kind prizes too, here's a round up of the investment prizes each startup won at the awards.

Zaymo, Brigham Young University — $885,000

Zaymo, a tool for e-commerce brands that embeds the shopping experience within customers’ email, won the most amount of money at the awards ceremony. The company won third place and a $50,000 Investment Prize sponsored by David Anderson, Jon Finger, Anderson Family Fund, Finger Interests, Greg Novak and Tracy Druce. Zaymo also won the following awards:

$200,000 OWL Investment Prize
$100,000 Houston Angel Network Investment Prize
$500,000 Softeq Venture Fund Prize
$15,000 Eagle Investors Prize
$20,000 Novak Druce Carroll Investment Prize

Boston Quantum, Massachusetts Institute of Technology — $455,000

Boston Quantum, which is using enterprise quantum computing software to disrupt the financial industry, won the second-most amount of investment prizes and sixth place in the competition.

$5,000 Chevron Technology Ventures Sixth-Place Cash Prize
$300,000 OWL Investment Prize
$125,000 Softeq Venture Fund Prize
$25,000 Urban Capital Network Diversity Investment Prize in partnership with South Loop Ventures

FluxWorks, Texas A&M University — $350,000

Based on the judges scores, the big winner was FluxWorks, a Texas company that's technology includes magnetic gears that are four times quieter than standard with 99 percent efficiency and can offer unprecedented reliability from outer space to under the sea and even inside the human body. The company won the $350,000 GOOSE Capital Investment Grand Prize.

Skali, Northwestern University — $300,000

Skali, which didn't make it into the prestigious finalist positions, still walked away with $300,000 courtesy of the Softeq Venture Fund Prize. Skali's technology aims to better equip flights with medical emergency assistance.

TierraClimate, Rice University — $280,000

TierraClimate, a marketplace for selling verified carbon offsets to corporate buyers, won fourth place and the Norton Rose Fulbright $5,000 Prize. The company also won a $200,000 Softeq Venture Fund Prize and the $75,000 OWL Investment Prize.

AirSeal, Washington University in St. Louis — $250,000

Another non-finalist that still scored big was AirSeal, a company that's created a simple blood test for cardiovascular diagnostics. The startup secured the $250,000 TMC Innovation Healthcare Investment Prize.

Sygne Solutions, Rice University — $200,000

Sygne Solutions, a startup on a mission of eliminating a group of chemicals known as PFAS in water through its patent-pending technology, won second place and the $100,000 Investment Prize, sponsored by David Anderson, Jon Finger, Anderson Family Fund, Finger Interests, Greg Novak and Tracy Druce. The company also received the $100,000 TiE Houston Angels Investment Prize.

BlueVerse, Texas Tech University — $145,000

BlueVerse, a startup with tech to merge social media with reviews and rewards for small businesses, didn't make the finals but walked away with on of the $125,000 Softeq Venture Fund Prizes and the $20,000 Novak Druce Carroll Investment Prize.

Atma Leather, Yale University —$130,000

Atma Leather, a material innovation company that's created plant-based leather from banana stems and other crop waste, came in fifth place and secured the $5,000 EY Fifth-Place Cash Prize. The startup also won:

$75,000 OWL Investment Prizes
$50,000 nCourage Investment Group’s Courageous Women Entrepreneurs Investment Prize

MyLÚA Health, Cornell University — $30,000

MyLÚA Health's AI technology supports the maternal health industry. The company won the $30,000 Pearland Economic Development Corporation Spirit of Entrepreneurship Prize.

Active Surfaces, Massachusetts Institute of Technology — $25,000

With its flexible and lightweight solar panel technology, Active Surfaces scored the $25,000 New Climate Ventures Sustainability Investment Prize.

Integrated Molecular Innovations, Michigan Technological University — $25,000

Integrated Molecular Innovations, which created a wearable device that can monitor hormone levels, won the $25,000 Southwest National Pediatric Device Consortium Prize.

MiraHeart, Johns Hopkins University — $25,000

MiraHeart, which created a non-invasive way of monitoring child heart conditions, also won the $25,000 Southwest National Pediatric Device Consortium Prize.

Biome Future, University of Florida — $20,000

Biome Future, which creates ocean-safe chemicals via microbes in corals, won one of the $20,000 Novak Druce Carroll Investment Prizes.

Citrimer, University of Michigan — $10,000

A sustainable materials company, Citrimer won the $10,000 NABACO RBPC Alumni Network Prize.

Thryft Ship, University of Georgia — $10,000

Thryft Ship, which streamlines the shipping process for social media sellers, won a $10,000 nCourage Investment Group’s Courageous Women Entrepreneurs Investment Prize.

Pathways, Harvard University — $5,000

Pathways, which is developing a full-stack sustainability platform for the construction industry, won $5,000 Shell Ventures Seventh-Place Cash Prize.

In addition to these investment prizes, the startups have the chance to score in-kind prizes. This year, that included:

$6,667 Baker Botts Legal Services In-Kind Prize to FluxWorks, Texas A&M University
$6,667 Baker Botts Legal Services In-Kind Prize to Sygne Solutions, Rice University
$6,667 Baker Botts Legal Services In-Kind PrizeFluxWorks to Zaymo, Brigham Young University
$10,000 New York Technology Capital CFO Consulting In-Kind to FluxWorks, Texas A&M University
EFN Mentoring Services to all startup competitors
Amazon Web Services to all startup competitors
Stage 2 Competition Entry to Sygne Solutions, Rice University

All 42 of the RBPC companies wins at least $950. In each of the three semi-final rounds, third place wins $2,000, fourth place wins $1,750, and fifth place wins $1,500. The wild card round, which acts as a second-chance competition for the companies that didn't originally make it to the finals, advances the wild card winner into the finals and also awards second place $1,000, third place $975, fourth place $950, and fifth place $950.

Here's what student teams from around the world were invited to compete in the Rice Business Plan Competition. Photo via rice.edu

Annual student startup competition in Houston names teams for 2023

getting pitch perfect

Rice Alliance for Technology and Entrepreneurship has named the 42 student startup teams that were extended invitations to compete in the 23rd annual Rice Business Plan Competition

The 2023 startup competition will take place on Rice University campus May 11 to 13, and the teams representing 37 universities from six countries will pitch to investors, mentors, and other industry leaders for the chance to win funding and prizes. Last year's RBPC doled out nearly $2 million in investment prizes.

This year, Rice saw its largest number of student startups applying for the RBPC internal qualifier from within campus. The university selected three to move on to compete at RBPC in May — Sygne Solutions, Neurnano Therapeutics, and Tierra Climate, which also received a total of $5,000 in cash prizes to these top three teams.

The 2023 RBPC will focus on five categories: energy, cleantech and sustainability; life science and health care solutions; consumer products and services; hard tech; and digital enterprise.

This invited companies, if they attend, will join the ranks of the 784 teams that previously competed in RBPC and have raised more than $4.6 billion in capital, as well as seen more than 50 successful exits including five IPOs.

The 2023 Rice Business Plan Competition invitees, according to Rice University's news release:

Active Surfaces, Massachusetts Institute of Technology
Adrigo Insights, Saint Mary’s University (Canada)
AirSeal, Washington University in St. Louis
Algbio, Yeditepe University (Turkey)
Arch Pet Food, University of Chicago
Astria Biosciences, University of Pittsburgh
Atma Leather, Yale University
Atop, UCLA
Biome Future, University of Florida
BioSens8, Boston University
BlueVerse, Texas Tech University
Boardible, Northwestern University
Boston Quantum, Massachusetts Institute of Technology
ceres plant protein cereal, Tulane University
Citrimer, University of Michigan
Dart Bioscience, University of Oxford (United Kingdom)
DetoXyFi, Harvard University
E-Sentience, Duke University
Edulis Therapeutics, Carnegie Mellon University
FluxWorks, Texas A&M University
Integrated Molecular Innovations, Michigan Technological University
Inzipio, RWTH Aachen University (Germany)
LoopX AI, University of Waterloo (Canada)
Magnify Biosciences, Carnegie Mellon University
MiraHeart, Johns Hopkins University
MyLÚA, Cornell University
Outmore Living, University of Texas
Pathways, Harvard University
Pediatrica Therapeutics, University of Arkansas
Perseus Materials, Stanford University
Pike Robotics, University of Texas
Quantanx, Arizona State University
Sheza, San Diego State University
Skali, Northwestern University
Sundial Solar Components, University of Utah
Thryft Ship, University of Georgia
Tierra Climate, Rice University
TrashTrap Sustainability Solutions, Visvesvaraya Technological University (India)
Unchained, North Carolina A&T State University
Unsmudgeable, Babson College
Vivicaly, University of Pennsylvania
Zaymo, Brigham Young University

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME